Ji Xing acquires Biogen’s BIIB131 for acute ischemic stroke
Share this article BIIB 131 is aimed at treating acute ischemic stroke (AIS) patients. Credit: CGN089/Shutterstock.com. Ji Xing Pharmaceuticals has acquired Biogen’s investigational drug, BIIB